RHOA and Behcet disease: Our results demonstrated that BD and BD+ antagonist treatments significantly reduced RhoA expression levels in peri‐infarct brain tissue compared with those in the model group, indicating the potential of BD to attenuate RhoA activity and promote neural regeneration in rats with PSS.